Nextcure Inc (NXTC)

Immunotherapies break into cold colorectal cancers at ASCO 2024 - BioCentury

BioCentury

Colorectal Cancer Market to Exhibit Moderate Growth Rate During by 2032, Investigates DelveInsight - EIN News

EIN News

Daily Market Movement: Nextcure Inc (NXTC) Sees a -3.73 Decrease, Closing at 1.55 – DWinneX - The Dwinnex

The Dwinnex

Reflecting on NextCure's (NASDAQ:NXTC) Share Price Returns Over The Last Year - Yahoo New Zealand News

Yahoo New Zealand News

Advanced Gastric Carcinoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and ... - openPR

openPR

The Globe and Mail - The Globe and Mail

The Globe and Mail

Reflecting on NextCure's (NASDAQ:NXTC) Share Price Returns Over The Last Year - Yahoo New Zealand News

Yahoo New Zealand News

HC Wainwright Reiterates Buy Rating for NextCure (NASDAQ:NXTC) - Defense World

Defense World

Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors - Yahoo Finance UK

Yahoo Finance UK

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

GlobeNewswire Inc.

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

GlobeNewswire Inc.

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024 - GlobeNewswire

GlobeNewswire

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

GlobeNewswire Inc.

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire Inc.

Small biotechs reveal reliance on Chinese CDMOs - BioCentury

BioCentury

Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait

Seeking Alpha

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate - Simply Wall St

Simply Wall St

NextCure Inc to Engage with Investors in Informal Talks - TipRanks.com - TipRanks

TipRanks

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

GlobeNewswire Inc.

NextCure to lay off 37% of staff, dial back research plans - Yahoo Finance

Yahoo Finance

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

GlobeNewswire Inc.

The FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies - Science

Science

Targeting VSTM-1 using anti-VSTM-1 agonist MAb reduces COPD pathology in vivo - BioWorld Online

BioWorld Online

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

GlobeNewswire Inc.

J&J jumps on ADC train, signs $1.7bn licensing deal with LegoChem - Pharmaceutical Technology

Pharmaceutical Technology

Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing

Zacks Investment Research

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

GlobeNewswire Inc.

NextCure (NXTC) Down on Shelving Plans to Develop Candidate

Zacks Investment Research

NextCure (NXTC) Down on Shelving Plans to Develop Candidate - Yahoo Finance

Yahoo Finance

Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

US Stocks Higher; Initial Jobless Claims Fall To 202,000

Benzinga

NextCure Provides Year-End Clinical Pipeline Updates

GlobeNewswire Inc.

US Stocks Higher; Initial Jobless Claims Fall To 202,000 - Amtech Systems (NASDAQ:ASYS), Cepton (NASDAQ:C - Benzinga

Benzinga

Advanced Gastric Carcinoma Clinical Trial Pipeline Accelerates as 50+ Pharma Companies Rigorously Developing ... - GlobeNewswire

GlobeNewswire

Cancer-focused biotech company Imvax raised $23M to advance clinical trials - Technical.ly

Technical.ly

Imvax Provides Corporate Update - Business Wire

Business Wire

Ashley Anne Martz Michael Felix Muzza | News, Sports, Jobs - Jamestown Post Journal

Jamestown Post Journal

NextCure, Underwriters Win Dismissal of Investor Class Action - Bloomberg Law

Bloomberg Law

Immune Checkpoint Inhibitors Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Key Companies in ... - PR Newswire

PR Newswire

Myelodysplastic Syndrome Market to Register Stunning Growth, Estimates DelveInsight | Key Players in the Market ... - GlobeNewswire

GlobeNewswire

Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer - Business Wire

Business Wire

NiKang Therapeutics Appoints Anne E. Borgman, M.D., to Board of Directors - citybiz

citybiz

Gastric Cancer Pipeline Space Brims With Novel Emerging Therapies with Over 200 Key Companies Working in the ... - PR Newswire

PR Newswire

NextCure and LegoChem Biosciences team up to develop antibody drug conjugates - BioPharma-Reporter.com

BioPharma-Reporter.com

NextCure and LegoChem Biosciences sign agreement to develop ADCs - Pharmaceutical Technology

Pharmaceutical Technology

NextCure discards antibody after candidate delivers no response in phase 2 cancer trial - Fierce Biotech

Fierce Biotech

Colorectal Cancer Clinical Trials Pipeline Analysis Featuring 125+ Key Companies by DelveInsight - GlobeNewswire

GlobeNewswire

NextCure Launches New GLP Lab, Expands In-House Capabilities - BioBuzz

BioBuzz

NextCure’s Clinical Development Strategy Centers People and Patients at the Core - BioBuzz

BioBuzz

Quality Culture Runs Deep at NextCure - BioBuzz

BioBuzz